CORRECTION -- Precipio continues to sign up and onboard HemeScreen™ customers
07 mars 2023 12h49 HE
|
Precipio, Inc.
NEW HAVEN, Conn., March 07, 2023 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Precipio, Inc. (NASDAQ: PRPO), please note that the 5th paragraph should read...
Precipio continues to sign up and onboard HemeScreen™ customers
07 mars 2023 12h00 HE
|
Precipio, Inc.
NEW HAVEN, Conn., March 07, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) continues to convert its sales pipeline into HemeScreen customers, with an...
Precipio Signs Another Major HemeScreen™ Customer
11 janv. 2023 10h00 HE
|
Precipio, Inc.
NEW HAVEN, Conn., Jan. 11, 2023 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announced another 4-year agreement with a new customer to bring HemeScreen™...
Global COVID-19 Diagnostics Market Projected to Garner $65,750.1 Million and Grow at 3.5% CAGR in the 2021-2028 Forecast Period [410-Pages] | Closure by Research Dive
19 oct. 2022 09h02 HE
|
Research Dive
New York, USA, Oct. 19, 2022 (GLOBE NEWSWIRE) -- According to the report published by Research Dive, the global COVID-19 diagnostics market is projected to garner a revenue of $65,750.1 million and...
Precipio to distribute HemeScreen® through Fisher Healthcare channel
20 juil. 2022 10h30 HE
|
Precipio, Inc.
NEW HAVEN, Conn., July 20, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), today announced that it has entered into an agreement with Fisher Healthcare,...
Bloodstream Infection Testing Market Expected to Garner $7,722.2 Million in the 2020-2027 Timeframe, Growing at 8.4% CAGR [247-Pages] | Research Dive
13 juin 2022 09h10 HE
|
Research Dive
New York, USA, June 13, 2022 (GLOBE NEWSWIRE) -- According to the latest report published by Research Dive, the global bloodstream infection testing market is predicted to rise at a tremendous CAGR...
Precipio customer American Oncology Network (AON) selected to present HemeScreen® technology case study at Industry leading clinical laboratory conference
26 avr. 2022 10h00 HE
|
Precipio, Inc.
NEW HAVEN, Conn., April 26, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO), is excited to announce its participation and the presentation of HemeScreen,...
Enzo Biochem Reports Results of its Annual Meeting of Shareholders
12 avr. 2022 08h30 HE
|
Enzo Biochem, Inc.
FOR IMMEDIATE RELEASE All Four Proposals Approved NEW YORK, NY, April 12, 2022 (GLOBE NEWSWIRE) -- Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading biosciences and diagnostics...
Hardy Diagnostics Now Offers the BioCode® MDx-3000
14 mars 2022 07h00 HE
|
Hardy Diagnostics
SANTA MARIA, Calif., March 14, 2022 (GLOBE NEWSWIRE) -- Hardy Diagnostics, a leader in manufactured and distributed microbiology products, is pleased to announce it is now the exclusive distributor...
New York State Approves Precipio’s HemeScreen for POL clinical use
18 nov. 2021 10h00 HE
|
Precipio, Inc.
NEW HAVEN, Conn., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces that its HemeScreen RUO assay has received the required approval from...